AAM: Generic medicines increase patient access more than government negotiated price controlsAAM is urging Congress and regulators to stop patent abuses and streamline approvals. FDA gives Lupin approval for bumetanide injectionBumetanide injection is indicated for the treatment of edema associated with congestive heart failure, hepatic disease and renal disease. Biosimilars Council urges House to pass patent thicket legislation S. 150 passed the Senate and was placed on the House of Representatives' suspension calendar. Alembic intros acitretin capsules Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Alembic intros fluphenazine hydrochloride tablets Fluphenazine hydrochloride tablets are are indicated in the management of manifestations of psychotic disorders. AAM, Biosimilars Council releases statement on statement on Senate Judiciary Markup of PREVAIL and PERA The Association for Accessible Medicines and its Biosimilars Council oppose passage of the PREVAIL Act and the PERA Act. Former FDA commissioner Scott Gottlieb will keynote AAM's annual meeting Scott Gottlieb also will moderate the CEOs Unplugged session, where healthcare executives will share their candid insights and industry perspectives. AAM, Biosimilar Council host patent abuse Congressional briefing AAM, The ERISA Industry Committee and Transparency-Rx sent a letter to Congressional leaders urging prompt legislative action. Hikma completes Xellia acquisition The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities and an R&D center in Zagreb, Croatia. Alimera Sciences takes legal action against ANI Pharmaceuticals to enforce merger agreement Alimera’s lawsuit asks the court to require ANI to comply with its obligations to complete the transaction as contemplated by the merger agreement. First Previous 19 20 21 22 23 Next Last
